The recent advance of Interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases

Yi-Ru Bai,Wei-Guang Yang,Xue-Hui Hou,Dan-Dan Shen,Sheng-Nan Zhang,Yan Li,Yan-Yan Qiao,Sai-Qi Wang,Shuo Yuan,Hong-Min Liu
DOI: https://doi.org/10.1016/j.ejmech.2023.115606
IF: 7.088
2023-06-29
European Journal of Medicinal Chemistry
Abstract:The interleukin-1 receptor associated kinase 4 (IRAK-4) is a member of serine-threonine kinase family, which plays an important role in the regulation of interleukin-1 receptors (IL-1R) and Toll-like receptors (TLRs) related signaling pathways. At present, the IRAK-4 mediated inflammation and related signaling pathways contribute to inflammation, which are also responsible for other autoimmune diseases and drug resistance in cancers. Therefore, targeting IRAK-4 to develop single-target, multi-target inhibitors and proteolysis-targeting chimera (PROTAC) degraders is an important direction for the treatment of inflammation and related diseases. Moreover, insight into the mechanism of action and structural optimization of the reported IRAK-4 inhibitors will provide the new direction to enrich the clinical therapies for inflammation and related diseases. In this comprehensive review, we introduced the recent advance of IRAK-4 inhibitors and degraders with regards to structural optimization, mechanism of action and clinical application that would be helpful for the development of more potent chemical entities against IRAK-4.
chemistry, medicinal
What problem does this paper attempt to address?